Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Cell
|
November 13, 2004
HDAC4: a corepressor controlling bone development
Bruce A Hug
Proceedings of the National Academy of Sciences of the United States of America
|
December 2, 2004
Fusion-protein truncation provides new insights into leukemogenesis
Jay L Hess, Bruce A Hug
Oncogene
|
May 25, 2004
ETO interacting proteins
Bruce A Hug, Mitchell A Lazar
International Journal of Cancer
|
November 9, 2011
A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Cancer Chemotherapy and Pharmacology
|
March 16, 2012
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
British Journal of Clinical Pharmacology
|
March 15, 2011
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
The Journal of Biological Chemistry
|
October 17, 2003
A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene
Bruce A Hug, Nazia Ahmed, Jonathan A Robbins, et al.
Journal of Clinical Pharmacology
|
December 15, 2010
Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Pigment Cell & Melanoma Research
|
May 22, 2015
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R Minor, Igor Puzanov, Margaret K Callahan, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2011
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Cell
|
November 13, 2004
HDAC4: a corepressor controlling bone development
Bruce A Hug
Proceedings of the National Academy of Sciences of the United States of America
|
December 2, 2004
Fusion-protein truncation provides new insights into leukemogenesis
Jay L Hess, Bruce A Hug
Oncogene
|
May 25, 2004
ETO interacting proteins
Bruce A Hug, Mitchell A Lazar
International Journal of Cancer
|
November 9, 2011
A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Cancer Chemotherapy and Pharmacology
|
March 16, 2012
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
British Journal of Clinical Pharmacology
|
March 15, 2011
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
The Journal of Biological Chemistry
|
October 17, 2003
A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene
Bruce A Hug, Nazia Ahmed, Jonathan A Robbins, et al.
Journal of Clinical Pharmacology
|
December 15, 2010
Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Pigment Cell & Melanoma Research
|
May 22, 2015
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R Minor, Igor Puzanov, Margaret K Callahan, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2011
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
Richat Abbas, Bruce A Hug, Cathie Leister, et al.
Page
of 2